

Highlights of ReV

Lois Levine, MA

According to a study published in *JAMA Dermatology* in 2022, between 0.76% (1.9 million) and 1.11% (2.8 million) adults in the United States have vitiligo; additionally, study investigators estimated that approximately 40% of adults with vitiligo may be undiagnosed.

With new treatments and discoveries about this dermatologic condition rapidly evolving, a Revolutionizing Vitiligo congress has been added to the Revolutionizing Atopic Dermatitis (RAD) weekend conference taking place this year from June 8-10 in Chicago, Illinois.

Conference chair Nanette B. Silverberg, MD, FAAD, Chief of Pediatric Dermatology for the Mount Sinai Health System and Site Director of Pediatric and Adolescent Dermatology for the Departments of Dermatology at Mount Sinai West and Mount Sinai Beth Israel, and clinical professor of Pediatrics and Dermatology at the Icahn School of Medicine at Mount Sinai, has this to say about the upcoming meeting: "During this exciting and critical time for the dermatology community, we felt it was important to hold CME-accredited conferences that focus exclusively on vitiligo and the complex information that has accrued around proper diagnosis, treatment, and management. Therefore, we created the Revolutionizing Vitiligo (ReV) Conference, an international, multidisciplinary conference dedicated to awareness, education, and discussion of the assessment and management of vitiligo."

Be prepared to learn about HSP-70 and its role in vitiligo; excellence in vitiligo clinical practice; systemic agents for vitiligo: the relationship of therapies to disease pathogenesis; and other essential information for the treatment and management of this disease.

Register to learn more about these topics, and others, at this year's ReV Conference, June 8-10, in Chicago, Illinois. Don't miss out!